Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Consensus Price Target from Analysts

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has earned a consensus rating of "Buy" from the six ratings firms that are currently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued a report on the stock in the last year is $82.50.

Several equities analysts have weighed in on the stock. Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Citigroup decreased their price objective on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. HC Wainwright upped their price target on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Finally, Bank of America upped their price target on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th.

Akero Therapeutics Trading Down 1.3%

NASDAQ AKRO traded down $0.70 on Thursday, reaching $54.20. 1,983,828 shares of the company were exchanged, compared to its average volume of 1,013,083. The business's fifty day moving average price is $45.88 and its 200 day moving average price is $41.17. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $4.32 billion, a P/E ratio of -27.79 and a beta of -0.16. Akero Therapeutics has a fifty-two week low of $21.02 and a fifty-two week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of ($1.01) by $1.91. Analysts forecast that Akero Therapeutics will post -3.99 earnings per share for the current year.

Insider Transactions at Akero Therapeutics

In other Akero Therapeutics news, CEO Andrew Cheng sold 30,000 shares of the company's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $35.23, for a total transaction of $1,056,900.00. Following the transaction, the chief executive officer now directly owns 624,324 shares in the company, valued at $21,994,934.52. This represents a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director G. Walmsley Graham bought 91,309 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were purchased at an average cost of $44.75 per share, for a total transaction of $4,086,077.75. Following the purchase, the director now owns 1,091,309 shares in the company, valued at $48,836,077.75. This represents a 9.13% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have sold 232,979 shares of company stock worth $10,935,650. 7.07% of the stock is currently owned by insiders.

Institutional Trading of Akero Therapeutics

Several hedge funds have recently made changes to their positions in AKRO. Rhumbline Advisers lifted its position in shares of Akero Therapeutics by 1.3% during the fourth quarter. Rhumbline Advisers now owns 105,686 shares of the company's stock worth $2,940,000 after purchasing an additional 1,310 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in Akero Therapeutics by 5.0% during the 4th quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company's stock worth $584,000 after buying an additional 1,000 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in Akero Therapeutics during the 4th quarter worth approximately $320,000. Charles Schwab Investment Management Inc. lifted its holdings in Akero Therapeutics by 1.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company's stock worth $15,042,000 after buying an additional 8,096 shares in the last quarter. Finally, AlphaQuest LLC raised its stake in shares of Akero Therapeutics by 32,588.0% in the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock valued at $227,000 after acquiring an additional 8,147 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.